(19)
(11) EP 1 558 615 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.10.2007 Bulletin 2007/41

(45) Mention of the grant of the patent:
29.08.2007 Bulletin 2007/35

(21) Application number: 03751149.0

(22) Date of filing: 21.10.2003
(51) International Patent Classification (IPC): 
C07D 473/30(2006.01)
C07D 473/40(2006.01)
A61K 31/52(2006.01)
 C07D 473/34(2006.01)
C07D 239/48(2006.01)
A61P 3/04(2006.01)
(86) International application number:
PCT/IB2003/004619
(87) International publication number:
WO 2004/037823 (06.05.2004 Gazette 2004/19)

(54)

PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS

PURINDERIVATE UND IHRE VERWENDUNG ALS LIGANDEN DES CANNABINOID REZEPTORS

COMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES CANNABINOIDES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 28.10.2002 US 421874 P

(43) Date of publication of application:
03.08.2005 Bulletin 2005/31

(73) Proprietor: Pfizer Products Inc.
Groton, CT 06340 (US)

(72) Inventor:
  • GRIFFITH, David A., Pfizer Global Research and Development
    Groton, CT 06340 (US)

(74) Representative: Motion, Keith Robert 
Pfizer Limited Patents Department Ramsgate Road
Sandwich, Kent CT13 9NJ
Sandwich, Kent CT13 9NJ (GB)


(56) References cited: : 
EP-A- 1 054 012
 US-A- 5 256 398
   
  • PERTWEE G. R.: "Cannabinoid receptor ligands" EXP. OPIN. INVEST. DRUGS, vol. 9, no. 7, 2000, pages 1553-1571, XP009024282 cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).